scholarly journals Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study

Oncoscience ◽  
2014 ◽  
Vol 1 (10) ◽  
pp. 665-673 ◽  
Author(s):  
Roberto Perez ◽  
Andrew V. Schally ◽  
Petra Popovics ◽  
Renzhi Cai ◽  
Wei Sha ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Hormone ◽  
Triple Negative Breast Cancer ◽  
Nude Mice ◽  
Triple Negative ◽  
Preclinical Study ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Efficacy Of Treatment

Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH)

2012 ◽  
Vol 9 (1) ◽  
Author(s):  
Stefan Buchholz ◽  
Stephan Seitz ◽  
Jörg B. Engel ◽  
Alberto Montero ◽  
Olaf Ortmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Experimental Studies ◽  
Growth Hormone Releasing Hormone ◽  
Breast Cancers ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone

AbstractTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is clinically negative for the expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2). Patients with TNBC have a worse clinical outcome, as measured by time to metastasis and median overall survival. Chemotherapy has been the mainstay of treatment of TNBC but responses are disappointing. A substantial proportion of TNBC expresses luteinizing hormone-releasing hormone (LHRH), receptors for LHRH, in addition to receptors for growth hormone-releasing hormone (GHRH). These receptors represent potential therapeutic targets. Potent antagonists of GHRH and LHRH receptors have been developed in recent years and these antagonists inhibit the growth, tumorigenicity and metastatic potential of various human experimental malignancies. These antagonists could be utilized for the treatment of TNBC. The targeted cytotoxic analog of LHRH, AN-152 (AEZS-108) containing doxorubicin, must also be strongly considered for therapy of TNBC. Experimental studies suggest the merit of clinical trials with LHRH antagonists and AEZS-108 in TNBC patients.

scholarly journals APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice

2019 ◽  
Vol Volume 11 ◽  
pp. 249-259
Author(s):  
Yayun Liang ◽  
Cynthia Besch-Williford ◽  
Matthew T Cook ◽  
Anthony Belenchia ◽  
Rolf A Brekken ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Lung Metastasis ◽  
Triple Negative Breast Cancer ◽  
Nude Mice ◽  
Breast Cancer Cells ◽  
Triple Negative

Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

2017 ◽  
Vol 13 (27) ◽  
pp. 2473-2477 ◽  
Author(s):  
Silvia Paola Corona ◽  
Giandomenico Roviello ◽  
Carla Strina ◽  
Manuela Milani ◽  
Giovanni Allevi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Hormone Analogs

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

2000 ◽  
Vol 60 (1) ◽  
pp. 71-79 ◽  
Author(s):  
Zsuzsanna Kahán ◽  
Zsuzsanna Kahán ◽  
József L. Varga ◽  
József L. Varga ◽  
Andrew V. Schally ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Nude Mice ◽  
Growth Hormone Releasing Hormone ◽  
Breast Cancers ◽  
Human Breast ◽  
Releasing Hormone
Sign in / Sign up

Export Citation Format

Share Document